DRI Raises $1.45 Bln with Third Fund
DRI Capital has collected $1.45 billion for its third fund, surpassing its $1 billion target. Along with available debt, Fund III will give DRI $3 billion of purchasing power. Drug Royalty III will acquire royalties from global pharmaceutical and biotechnology companies, research institutions, universities, and inventors. Atlantic-Pacific Capital was placement agent for Fund III. DRI Capital, of Toronto, buys royalty streams on approved and clinical stage pharmaceutical products.
9 September 2013•2 mins read
